Visionary Ventures
Newport Beach life-sciences venture firm (founded 2016, Octane lineage) investing Series A through commercialization in ophthalmology, medical aesthetics, cardiovascular, and neurovascular companies. Public materials cite ~$30M Fund I, ~$150M Fund II, and a planned $250M Fund III (Jun 2025 OCBJ). Leverages 75+ ophthalmology KOL investor-partners for diligence and deal flow in OC's medtech cluster.
Typical check size
$1M-$10M (stage-based estimate)
Founded
2016
Headquarters
Newport Beach, CA
AUM
~$180M+ across Fund I–II (indicative; Fund III targeting $250M)
Rounds they lead
Series A
Series B
Rounds they invest
Seed
Series A
Series B
Growth
Related investment articles
FAQs about Visionary Ventures
Stage fit, check size, thesis, and how founders typically approach this firm — based on public sources and our directory.
Life-sciences companies — primarily ophthalmology devices and drugs, plus medical aesthetics, cardiovascular, and neurovascular — from Series A toward commercialization.
Newport Beach, California, with additional Aliso Viejo presence. Orange County is cited as the global ophthalmology cluster on the firm website.
Public site cites $5M–$15M target investments at Series A+; LinkedIn materials mention $500K–$5M in earlier rounds — confirm per deal.
75+ ophthalmology key opinion leaders participate as investor-partners for screening, diligence, and commercialization intros — not a generic healthtech fund.
OCBJ coverage links Fund II portfolio to Irvine-based Tarsus Pharmaceuticals (Nasdaq: TARS) and Aliso Viejo-based RxSight (Nasdaq: RXST).
Co-founded from the Octane accelerator ecosystem a decade ago; separate from Octane's Boost micro-VC but shares SoCal medtech network density.
Aims to be lead or co-lead at Series A+ in ophthalmology and adjacent life-science verticals.
Bring clinical evidence and a KOL-friendly commercial path; start at visionaryvc.com with ophthalmology or adjacent cardiovascular/neurovascular fit.